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Chronic lymphocytic leukemia (CLL),' the most common leukemia, may be
considered a malignancy of the CD5 (Leu-1) B cell . The small lymphocytes that
accumulate in the peripheral blood of affected patients generally coexpress both
sIg and the pan-T cell surface protein CD5 (1-3) . Patients with CLL may have
seemingly paradoxical, yet coincident, immunologic defectsof impaired humoral
immunity and augmented autoimmune reactivity (4). Furthermore, it has been
reported that a high proportion of CLL cells express surface IgM (sigM) with
rheumatoid factor (RF) autoantibody reactivity (5) . In contrast to other leuke-
mias, the incidence of CLL is not increased after ionizing radiation, but rather
displays a familial tendency, suggesting that genetic factors possibly contribute
to the pathogenesis of this disease (6) . Recently, genetic factors have been found
to influence the proportions of circulating lymphocytes that coexpress CD5 and
sIg in normal adults (7). Such normally occurring CD5 B cells have been
implicated in the regulation ofIg productionby other B cells, andas an important
source of IgM autoantibodies (8-11) . Understanding the nature of Ig variable
region gene expression in CLL may provide insight into the physiology of
autoantibody production by theCD5 B lymphocyte .
Recently, we discovered that a surprisingly high proportion of patients with
CLL have malignant cells reactive with a murine monoclonal andidiotypic
antibody, 17 .109 (12) . This antibody, prepared against the IgMRF cryoglobulin,
SIE, recognizes a K light chain-associated crossreactive idiotype (CRI) present
on over one-third of all human IgM RF paraproteins isolated from unrelated
patients with Waldenstrom's macroglobulinemia or cryoglobulinemia (13-15).
In contrast, the 17.109 antibody does not react substantially with either normal
pooled Ig or circulating B lymphocytes from normal adults (12, 15). However,
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in a survey of >30 patients, 5 of the 20 (25%) K light chain-expressing CLL
reacted with this antibody (12) .
To determine the precise molecular basis for the 17.109-CRI expression in
CLL, we performed nucleic acid sequence analyses of the K light chain variable
regions expressed by 17.109-reactive leukemic B lymphocytes from two unre-
lated individuals . We found striking homology between the K variable region
genes (VK genes) expressed by these leukemic B cells . Furthermore, these ex-
pressed VK genes are homologous to a nonrearranged VK gene that previously
had been isolated from placentalDNA and theorized to encode x variable regions
of IgM autoantibodies (16) . The implications of these findings relative to the
physiology of the CD5 B cell, and the etiology and potential immunotherapy of
CLL are discussed .
Materials and Methods
Cells.
￿
Leukemic cells were isolated from the peripheral blood oftwo patients (HAH
andHIC) with sIgMKCLLpreviously noted to react with the 17.109 antibody (12). Before
RNA isolation, a sampling from the cells was tested for expression of K sIg bearing the
17.109-CRI, using R-phycoerythrin-conjugated 17.109 (PE-17.109) and fluorescein-con-
jugated murine mAb specific for the constant portion of the human K or X light chain
(12).
RNA Sequencing.
￿
Polyadenylated RNA was isolated on oligo-dT-cellulose from total
RNA extracted from 17.109' CLL using 6M guanidium isothiocyanate (17, 18). Oligo-
nucleotides dCTCACAGATGGCGGGAAGATGAA, dAACCTGTCTGGGATGC, or
dGGGTGCCTGGAGACTG, correspondingto the K constant region (positions 116-124),
third (positions 58-63) or first (positions 6-11) variable region frameworks, respectively,
were used to primecDNA synthesis of 10-12 kg of polyadenylated RNA for sequencing
by the dideoxynucleotide chain-termination method using a_[35S]ATP, a-[g2P]CTP or a-
[s2P]ATP (New England Nuclear, Boston, MA) as described (19, 20) . Different radiola-
beled nucleotides and reaction mixtures were used to resolve sequencing ambiguities .
cDNA Isolation.
￿
4 ug of polyadenylated RNA were used to construct a cDNA expres-
sion library of>2.6 X 106 independent recombinants in agt10 as described (21) . Recom-
binant Xphageplaques lifted onto nitrocellulose were hybridized with s2P-labeled synthetic
oligonucleotides specific for the constant and variable region of the Ig K light chain using
conditions described previously (12, 21) . Desired recombinant phage were isolated to
homogeneity. The insert DNA was purified and then ligated into the polylinker site of a
pUC19 plasmid (Bluescribe; Vector Cloning System, San Diego, CA) as described (22) .
DNA Sequencing.
￿
Escherichia coli strainJM83 was transformed with the ligated plasmid
DNA using the procedure ofHanahan (23). We identified colonies with plasmids contain-
ingthedesiredrecombinant insert andextractedtheplasmidDNA fordsDNAsequencing
as described (24). Oligonucleotides used in mRNA sequencing were each used to prime
DNA synthesis for sequencing using a-[a5S]CTP(New England Nuclear) as described (20,
25) . Computer programs of the University of Wisconsin Genetics Computer Group were
used to analyze sequence data and to prepare figures on a Digital VAX750 computer .
Oligonucleotides .
￿
Oligonucleotides were as described (12) . Labeling the 5' ends of the
oligonucleotides with .y-[s2P]ATP was achieved usingpolynucleotide kinase (26) .
Results
Dual immunofluorescence staining of the CLL cells from patients HAH and
HIC demonstrated that all leukemic cells expressed CD5, sIg, and the 17 .109
idiotope (Fig . 1) . The staining intensity of HAH with PE-17.109 was ^-10-fold
greater than the PE-17.109 staining intensity of HIC. In dual immunofluores-
cence studies, however, the relative staining intensity of PE-17.109 was propor-842
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FIGURE 1 .
￿
Dual immunofluorescence detected at 572 nm (red, ordinate)and 535nm (green,
abscissa) of peripheral blood lymphocytes from patient HAH (top row) or HIC (bottom row) .
Depicted arethecontour histograms of the autofluorescence ofHAH and HIC cells (left), of
cells stained with PE-17 .109 and FITC-(IgGI anti-X light chain) (middle), or PE-17 .109 and
FITC-(IgGI anti-a light chain) (right) .
tional to that of an anti-a constant region FITC-labeled mAb. Thus, quantitative
differences in the staining intensity of HIC and HAh with the 17.109 antibody
were a function of the relative amounts of slg expressed and not of qualitative
differences in the ability of the 17.109 antibody to bind to the different cell
populations.
Nucleic acid sequence analyses of polyadenylatedRNA isolated from theCLL
cells of each patient demonstrate that the K variable regions are highly homolo-
gous (Fig . 2) . Complete resolution of the nucleic acid sequence of the V,, RNA
derived from HIC was possible through repeated sequencing reactions using
different oligonucleotide primers . Because of limiting quantities of polyadeny-
lated RNA, multiple sequencing reactions of the RNA from HAH using each of
the synthetic oligonucleotides were not possible . The nucleic acid sequence
derived from priming reactions with the oligonucleotide complementary to the
sense strand of the K constant region (positions 116-124) revealed one base
difference in the HAH sequence from that of HIC at position 93 in the third
complementarity determining region (CDR3), resulting in a structurally conserv-
ative amino acid substitution ofThr for Ser. Despite different reaction mixtures,
the sequence of both RNAs could not be resolved for one base in the codon for
the amino acid at position 81, numbering according to Kabat et al . (27) . This is
consistent with the two RNAs having similar secondary structure through se-
quence homologies . From the data in Fig . 2, it can be deduced that the leukemic
cells from both patients use a nonmutated J.1 segment in their light chainRNA----------------LEADER SEQUENCE---------------
MetGluThrProAlaGlnLeuLeuPheLeuLeuLeuLeuTrpLeuPro
HIC (R) ATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTGCTACTCTGGCTCCCA
HAH 14 .1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HAH 14 .2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HAH 16 .1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Humkv325
￿
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .GGTGAG000A
Humkv325 ACATGGGATGGTTTTGCATGTCAGTGAAAACCCTCTCAAGTCCTGTTACCTGGCAACTC
Humkv325 TGCTCAGTCAATACAATAATTAAAGCTCAATATAAAGCAATAATTCTGGCTCTTCTGGG
Humkv325 AAGACAATGGGTTTGATTTAGATTACATGGGTGACTTTTCTGTTTTATTTCCAATCTCA
Humkv325 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Humkv325 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Humkv325 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Humkv325 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Humkv325
￿
. . . . . . . . . . . . . . .G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
FIGURE 2 .
￿
Nucleic acid sequence comparison of 17.109-reactive CLL (HIC and HAH) and
Humkv325 . Listed to the left are the names of the nucleic acid sequences . Sequences derived
from RNA sequencing are listed by the name followed by an R. Sequences HAH 14.1,HAH
14.2 andHAH16.1 are independent K light chain cDNA clones derived fromHAH polyaden-
ylated RNA. Below the nucleic acid sequence of HIC are depicted nucleotides at positions
where there exists differences in the compared sequence . Dots indicate sequence homology,
Xindicates sequence base ambiguity . Genomic bases ofHumkv325 between the leader sequence
andthe coding region that are deleted duringmRNA processing are listed withoutcomparison
to the other sequences. Above the nucleic acid sequence is depicted the three-letter code of
the deduced amino acid sequence for HIC. The deduced amino acid sequence of HAH is
identical to that of HIC except at position 93, where HAH encodes Thr instead of Ser, and
at position 96, where HAH encodes Arg instead of Trp . HAH encodes Glu at position 82,
where the sequence of HIC could not be resolved with certainty. Listed above the deduced
amino acid sequence are amino acid position numbers according to Kabat et al . (27) and
descriptions indicating the position of the leader sequence, the CDR1, CDR2, andCDR3 and
thej region . Thesesequencedata have been submitted to theEMBL/Gen Bank Data Libraries
under the accession number Y00648 .
81 89--CDR3.----93--__---
SerArgLeuGluProXxxAspPheAlaValTyrTyrCysGlnGlnTyrGlySerSerPro
HIC (R) AGCAGACTGGAGCCTXAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCT
HAH (R) . . . . . . . . . . . . . . .X . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .C . . . . . . .
HAH 14 .1 . . . . . . . . . . . . . . .G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .C . . . . . . .
HAH 14 .2 . . . . . . . . . . . . . . .G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .C . . . . . . .
HAH 16 .1 . . . . . . . . . . . . . . .G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .C . . . . . . .
-56
ThrGlyileProAspArgPheSerGlySerGlySerGlyThrAspPheThrLeuThrlle
HIC (R) ACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATC
HAH (R) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HAH 14 .1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HAH 14 .2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HAH 16 .1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
50-----_-Cpp2___--
TyrGlnGlnLysProGlyGlnAlaProArgLeuLeuIleTyrGlyAlaSerSerArgAla
HIC (R) TACCAGCAGAAACC'iGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCC
HAH (R) . . . . . . . . . . . .
HAH 14 .1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HAH 14 .2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HAH 16 .1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24----------27A---- Dg1-----------34
GluArgAlaThrLeuSerCysArgAlaSerGlnSerValSerSerSerTyrLeuAlaTrp
HIC (R) GAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGG
HAH 14 .1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .C . . . . . . . . . . . . . . . . . . . . .
HAH 14 .2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .C . . . . . . . . . . . . . . . . . . . . .
HAH 16 .1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .C . . . . . . . . . . . . . . . . . . . . .
96----------------- 1----------------- 109-----CK-----
TrpThrPheGlyGlnGlyThrLysValGluIleLysArgThrValAlaAlaPro
HIC (R) TGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGAACTGTGGCTGCACCA
HAH (R) C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HAH 14 .1 C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HAH 14 .2 C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HAH 16.1 C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1
AspThrThrGlyGluIleValLeuThrGlnSerProGlyThrLeuSerLeuSerProGly
HIC (R) GATACCACCGGAGAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCA(EGG
HAH 14 .1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HAH 14 .2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HAH 16 .1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .844
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transcripts (28). Differences between HIC and HAH at position 96 may be
attributed tofunctional diversity.
To ascertain the complete nucleic acid sequence of the expressed light chain
variable region of HAH and to evaluate for potential VK RNA transcript heter-
ogeneity, we constructed an expression library in Xgt10 of cDNA generated
from the polyadenylated RNA of HAH. >10' independent recombinant phage
plaques from a nonamplified cDNA library were screened using a2P-labeled
oligonucleotides specific for the K constant region (12). Nitrocellulose filter-
immobilized DNA from several independent plaques hybridized intensely with
this probe. Such plaques were isolated to homogeneity and their insert DNA was
subcloned into the pUC19 plasmid vector for dsDNA sequence analyses.
Three independent full-length K light chain cDNA clones were analyzed. The
complete nucleic acid sequences ofthe VK regions of each of these isolates were
identical, consistent with the Ig RNA transcripts in the population of leukemic
CLL cells having limited heterogeneity (Fig. 2). These sequences agreed with
the RNA sequence dataofHAH, and demonstrated >99% nucleicacid sequence
homology with the VK mRNA sequence expressed by leukemic cells from HIC.
The VK sequences expressed by HIC and HAH show striking homology with
a nonrearranged VK gene recently isolated from placental DNA, designated
Humkv325 (or VKRF) (16). The coding region of Humkv325 is identical to the
elucidated cDNA VK gene sequence ofHIC and is >99% homologous to that of
HAH (Fig. 2). In addition, the deduced leader sequences of all three VK genes
are identical. Such sequence homology strongly argues that the leukemic cells of
HIC and HAH express Humkv325 with little or no somatic mutation.
Comparison of the deduced amino acid sequences of the CLL K light chains
with the reported K light chain variable region sequences of several 17.109' RF
paraproteins isolated from patientswith Waldenstrom'smacroglobulinemiadem-
onstrates close homology (Fig. 3) (27, 29-33). The VK gene encoded K light chain
variable region of the immunogen used to induce the murine 17.109 antibody,
SIE, differs from the deduced HIC or HAH sequence by two or three VK gene-
encoded amino acids, respectively, this representing >97% sequence homology.
Even greater homology is noted between the deduced cDNA sequences and VK
sequences of other 17.109' IgM RF paraproteins, GLO, CUR, and GAR (Fig.
3). The amino acid sequence encoded by the VK gene for each ofthese parapro-
teins differs from HAH only at position 93, these paraproteins having Ser at this
position rather than the structurally similar Thr. In none of the sequenced
17.109' K light chains does there appear a Thr at this position. However, Thr is
found at position 93 in a few other sequenced VKIII proteins not tested for
reactivity with 17.109 (27). Thus we can not exclude the possibility that the Thr
at position 93 ofHAH results from geneticpolymorphism in the Humkv325 gene
rather than from a point mutation in the Ser codon.
TheJ regions ofmost 17.109' K light chain paraproteins are probably encoded
by the same JK segment used by HIC and HAH, namely JK1 (27-33). The
exceptions are proteins GOT and GAR, which most likely use the structurally
similarJK2 segment, and KAS, which most likely uses JK4. Differences between
these proteins at position 96 reflect junctional diversity occurring during the
rearrangement of the VK gene with theJ region. Whether there is an obligatoryKIPPS ET AL. 845846
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structural requirement for the sequences to use either J.1, JK2 or JK4 to react
with the 17.109 antibody cannot be determined. The sample bias also may reflect
the preferential usage of the different JK segments by the malignant B cells
expressing Humkv325.
Comparison of the deduced amino acid sequences of the VK genes expressed
by 17 .109-reactive CLL with the structurally related but 17.109- K light chains
of IgMK RF paraproteins WOL and NEU (29-32), revealsaminoacid differences
in the first and third CDR (Fig. 3). In addition, NEU differs at two positions in
the second framework. Of note, both 17.109- K light chains have structurally
nonconservative differences in the third CDR. NEU has Ala instead of Thr or
Ser at position 93, and Cys in lieu of Arg at position 96. Although WOL has Ser
at position 93, it has nonconservativedifferencesat positions94 (with Leu instead
of Ser) and 95 (with Gly instead of Pro). Despite sharing 95% overall homology
with the deducedaminoacid sequences of HIC and HAH, the structural changes
resulting from these third CDR differences may account for the inability of
isolated NEU and WOL K chains to react with the 17.109 antiidiotypic antibody.
These data also serve to emphasize that even minor differences in the primary
sequence encoded by Humkv325 can result in loss of light chain reactivity with
the 17.109 antibody.
Discussion
This study demonstrates that the presence of a major CRI in human CLL is
secondary to expression of the same VK gene that has been highly associated with
IgM autoantibodies. Previously, we noted in a study of >30 patients with CLL
that one-quarter of the K light chain-expressing CLL possessed a CRI recognized
by the 17 .109 mAb (12). Here we present sequence analyses of K light chain
polyadenylated RNA or cDNA derived from two unrelated patients with CLL
bearing the 17 .109-CRI . The results reveal striking sequence homology between
the expressed VK genes and a VK gene previously isolated from placental DNA,
designated Humkv325 (or VKRF) (16). We conclude that a relatively high per-
centage of patients with CLL have leukemic cells that express the Humkv325
gene.
Estimates of the number of distinct VK genes in man range from 25 to 50 (34-
38). To date, a total of 34 VK genes have been distinguished (33-43). Of these,
8 belong to the VKIII subgroup (43, 45). Only one of these, Humkv325, has
nucleic acid sequence homology with the VK gene expressed by leukemic cells
from HIC. Moreover, only Humkv325 can encode the is light chain paraproteins
that are recognized by 17 .109 without sequence permutations. Thus, the high
frequency at which 17 .109 is noted to react with leukemic cells from unrelated
patients with CLL argues that antibody V genes are expressed nonstochastically
in this disease.
The repeated use of Humkv325 in CLL raises the possibility that the variable
region protein encoded by this gene may be related to the leukemogenic process.
The 17 .109-CRI has been associated with multiple different IgM autoantibodies,
including antibodies reactive with low-density lipoproteins, intermediate fila-
ments, and autologous erythrocytes in addition to RF (13, 15, 29-32, 46-50).
Furthermore, the sIg on a high proportion of CLL have been reported to haveKIPPS ET AL.
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such RF activity (5) . It is possible that B lymphocytes with self-reactive sIg may
be stimulated to divide in the absence of exogenous antigen, thereby increasing
their likelihood for chance transformation. Also, autoreactive sIg may serve to
focus a transforming agent onto the cell, for example, by binding either a
leukemogenic virus or an antigen-antibody complex containing such a trans-
forming agent (51) . In this light, it is noteworthy thata recently elucidated amino
acid sequence of the K light chain variable region from a human anticytomega-
lovirus (CMV) IgGK shares extensive homology with the deduced amino acid
sequences of HIC and HAH, and probably is encoded by the same VK gene (52) .
Alternatively, the high frequency of 17.109-reactive CLL may reflect a non-
stochastic use of the Humkv325 gene by the physiologic counterpart to the CLL
B cell, namely the CD5 B cell . These cells constitute a minor lymphocyte subset
that has been shown to be enriched for cells synthesizing IgM autoantibodies
(31, 32) . Consistent with this notion, we have identified hybridomas generated
from autoreactive CD5 B cells that express the 17.109-CRI and the Humkv325
gene (unpublished observations) . IfCD5 B cells express sIg with low-avidity anti-
self reactivity, they may be stimulated constitutively throughout the life span of
the individual . Thus, these cells may serve as a renewing stem cell population
for B lymphocytes that somatically diversify their expressed Ig V genes during
immune responses to exogenous antigens . Alternatively, CD5 B cells may rep-
resent adistinct cell lineage that uses autoreactive sIg to focus immune complexes
and debris from senescent cells onto accessory cells . In either case, selective
pressure would be exerted on V genes that may encode antibodies with such
autoreactive specificities . Furthermore, such antibody V genes may be expressed
preferentially in early B cell ontogeny when CD5 B cells constitute a major
lymphoid subpopulation (53, 54) .
Our studies also indicate that the malignant B cells from patients with CLL
constitute a relatively homogeneous population that have undergone little or no
Ig V gene somatic mutation . This stands in marked contrast to the relatively
high rate of somatic mutation detected in human B cell follicular lymphomas
that do not express the CD5 antigen (55-59). Heterogeneity in the idiotype(s)
expressed by these latter tumors has confounded attempts at passive immuno-
therapy with solitary antiidiotypic antibodies, as idiotype variants arise at high
frequency (56-59). Such idiotypic heterogeneity in follicular lymphomas also is
noted before therapy with antiidiotypic antibodies (55) . Levy and his colleagues
(56, 59) have demonstrated that such idiotypic heterogeneity within a given
follicular lymphoma results through an ongoing process of somatic mutation in
both expressed heavy and light chain V genes . In contrast, the correlation
between the cell surface levels of 17.109-CRI and K light chain on leukemic cell
populations from patients HIC and HAH argues against extensive idiotypic
heterogeneity in CLL. Indeed, sequence comparisons of rc light chains tested for
reactivity with 17 .109 indicate that subtle changes in the primary sequence often
result in the complete loss of idiotypic reactivity (Fig . 3) . Furthermore, the VK
genes expressed by the leukemic cells from HIC and HAH have a paucity of
conservative or silent nucleic acid base substitutions . To be sure, the data
presented do not exclude the possibility that Ig V gene somatic mutation may
occur in CLL, this producing idiotype variants within a CLL population that
may expand under selective pressure . Such idiotype variants also may become848
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evident after immunotherapy with antiidiotypic antibodies. However, the ho-
mogeneous fluorescence staining with the 17.109 antiidiotype and the identical
VK region nucleic acid sequences of three independent K cDNA clones derived
from the leukemic cells of HAH is consistent with the notion that the V genes
expressed by a given CLL population have limited heterogeneity.
Our results have important implications for immunotherapy of CLL (and
perhaps Waldenstrom's macroglobulinemia). A disease derived from a minor B
cell subset expressing sIg that uses a restricted set of Ig V genes with minimal
somatic mutation should be particularly amenable to passive immunotherapy
with antiidiotypic antibodies. Furthermore, it may be anticipated that other CRIB
will be found that are highly associated with this malignancy. The further
identification and characterization of such conserved CRIB is essential and would
facilitate the generation of batteries of mAbs suitable for treating large numbers
of CLL patients.
Summary
Recently the minor B cell subpopulation that expresses the CD5 (Leu-1)
antigen has been implicated as a source of IgM autoantibodies. Chronic lympho-
cytic leukemia (CLL), the most common leukemia in humans, represents a
malignancy of small B lymphocytes that also express the CD5 antigen. However,
little is known concerning the antibody variable region genes (V genes) that are
used by these malignant CD5 B cells. We have found that a relatively high
frequency of CLL patients have leukemic B cells with surface immunoglobulin
(s1g) recognized by 17.109, a murine mAb specific for a K light chain associated
crossreactive idiotype (CRI) associated with rheumatoid factor and other IgM
autoantibodies. Flow cytometric analyses revealed that the relative expression of
the 17.109-CRI by circulating leukemic B cells was directly proportional to the
levels of sIg K light chain, indicating that there exists stable idiotype expression
in the leukemic population . To examine this at the molecular level, the nucleic
acid sequences encoding the Ig K light chains of two unrelated patients with CLL
bearing sIg with the 17.109-CRI were determined. Analyses of multiple inde-
pendent K light chain cDNA clones did not reveal any evidence for sequence
heterogeneity in the CLL cell population. Furthermore, the nucleic acid se-
quences expressed by the leukemic cells of these two patients were identical or
very homologous to a germline VK gene isolated from placental DNA, designated
Humkv325, or "VKRF" because of its association with IgM autoantibodies. This
study suggests; (a) that the malignant CD5'' B lymphocytes in CLL use the same
VK gene that has been highly associated with IgM autoantibodies and (b) that the
expression of V genes is stable in CLL, in contrast to other B cell malignancies
examined to date. We propose that many CLL cases represent malignancies of
autoreactive CD5 B cells that use a restricted set of conserved V genes. This
property may render CLL particularly amenable to immunotherapy with anti-
idiotypic antibodies.
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